Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Correlation between SUV and Ki

    2020-08-18


    Correlation between SUV and Ki 67 in breast cancer Surov et al. 377
    Table 1. Data About Filipin Complex Involved Studies
    Autors Year Country Design Histo-pathology Patients Receptor status
    Tracer
    Avril et al. [15] 2001 Germany retrospective different 46 different
    Bitencourt et al. [16] 2014 Brazil prospective different 50 different
    Buck et al. [17] 2002 Germany retrospective different 75 different
    Cheng et al. [18] 2013 China retrospective n.r. 20 ER positive
    Choi et al. [19] 2018 South Korea retrospective different 117 Triple negative
    Cochet et al. [20] 2012 France prospective n.r. 40 different
    Contractor et al. [21] 2011 United Kingdom prospective n.r. 18 different
    Crippa et al. [22] 2015 Italy prospective different 15 different, none triple negative 18F-FLT
    De Cremoux et al. [23] 2018 France retrospective different 75 Luminal types
    Ege Aktas et al. [24] 2017 Turkey retrospective IDC 65 different
    Garcia Vicente et al. [26] 2012 Spain prospective different 68 different
    GarcĂ­a-Esquinas et al. [25] 2014 Spain prospective n.r. 43 different
    Groheux et al. [27] 2018 France prospective different 55 Triple negative
    Humbert et al. [28] 2014 France prospective different 61 Luminal types
    Ikenaga et al. [29] 2007 Japan retrospective different 45 different
    Jacobs et al. [30] 2011 USA prospective different 6 different
    Jena et al. [31] 2017 India retrospective IDC 69 different
    Kenny et al. [32] 2005 United Kingdom prospective different 15 n.r.
    Koo et al. [33] 2015 South Korea retrospective different 103 Triple negative
    Koolen et al. [34] 2012 The Netherlands prospective different 214 different
    Kostakoglu et al. [35] 2015 USA prospective different 72 different
    Kurland et al. [36] 2012 USA prospective different 40 different
    Marti-Climent et al. [37] 2014 Spain prospective different 30 different
    Nishimukai et al. [38] 2017 Japan retrospective n.r. 163 different, none triple negative 18F-FDG
    Shimoda et al. [39] 2007 Japan retrospective different 37 different, none triple negative 18F-FDG
    Smyczek-Gargya et al. [40] 2004 Germany prospective n.r. 12 different
    18F-FLT, 18F-FDG Soussan et al. [41] 2014 France retrospective different 54 different
    Tchou et al. [42] 2010 USA retrospective different 41 different
    Tokes et al. [43] 2015 Hungary retrospective different 42 different
    Tural et al. [44] 2015 Turkey retrospective different 73 different
    Woolf et al. [45] 2014 United Kingdom prospective IDC and ILC 19 different
    Yang et al. [46] 2013 China retrospective n.r. 18 different
    IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; HER 2, human epidermal growth factor receptor 2; 18F-FLT, 18F-fluorthymidin; 18F-FDG (fluoro-D-glucose)
    degree of correlation between SUVmax and Ki-67 [53]. So, correlation coefficients ranged from 0.81 in thymic carcinoma to -0.22 in malignant melanoma [53]. In most malignancies, only moderate correlations between the analyzed parameters were identified [53].
    Previously, numerous reports analyzed relationships between PET parameters and expression of Ki-67 in BC with very inconsistent results. So, a very wide spectrum of correlation coefficients between SUVmax and Ki-67 was reported. Furthermore, most studies investigated small samples ranging from 6 to 75 patients/tumors and only four studies investigated samples over 100 patients [20,33,34,38]. Therefore, the reported data cannot be considered as evident. These facts question the possibility to use PET parameters as surrogate biomarkers for proliferation activity in BC. 
    The present analysis identified moderate correlations between SUVmax derived from FDG PET and expression of Ki-67 in BC (0.40). In most acquired studies, slightly-to-moderate correlations were
    observed. Only in the study of Kurland et al., the reported correlation coefficient was -0.07 [36] and must be seen as an outlier [36]. In this study, the decline of FDG-PET uptake and Ki-67 after aromatase inhibitors and trastuzumab therapy was investigated [36]. The negative correlation at baseline might be caused by a heterogenous patient sample comprising metastasized and not metastasized patients. However, in the aromatase group a strong correlation regarding therapeutic induced decline of Ki-67 and FDG-PET was identified (r=0.77), indicating that in specific subgroups the associations between imaging and histopathology substantial can differ.